DE69202594T2 - Zusammensetzung gegen Katarakt. - Google Patents

Zusammensetzung gegen Katarakt.

Info

Publication number
DE69202594T2
DE69202594T2 DE69202594T DE69202594T DE69202594T2 DE 69202594 T2 DE69202594 T2 DE 69202594T2 DE 69202594 T DE69202594 T DE 69202594T DE 69202594 T DE69202594 T DE 69202594T DE 69202594 T2 DE69202594 T2 DE 69202594T2
Authority
DE
Germany
Prior art keywords
glutathione
dicarboxyethyl
salt
cataract
ethanol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69202594T
Other languages
German (de)
English (en)
Other versions
DE69202594D1 (de
Inventor
Yoshimasa Abe
Ogata Kazumi
Shinji Ohmori
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Senju Pharmaceutical Co Ltd
Original Assignee
Senju Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senju Pharmaceutical Co Ltd filed Critical Senju Pharmaceutical Co Ltd
Publication of DE69202594D1 publication Critical patent/DE69202594D1/de
Application granted granted Critical
Publication of DE69202594T2 publication Critical patent/DE69202594T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DE69202594T 1991-02-27 1992-02-22 Zusammensetzung gegen Katarakt. Expired - Fee Related DE69202594T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP11964591 1991-02-27

Publications (2)

Publication Number Publication Date
DE69202594D1 DE69202594D1 (de) 1995-06-29
DE69202594T2 true DE69202594T2 (de) 1995-09-28

Family

ID=14766578

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69202594T Expired - Fee Related DE69202594T2 (de) 1991-02-27 1992-02-22 Zusammensetzung gegen Katarakt.

Country Status (9)

Country Link
EP (1) EP0501354B1 (enExample)
JP (1) JPH05112463A (enExample)
KR (1) KR0168459B1 (enExample)
AT (1) ATE122892T1 (enExample)
CA (1) CA2061133A1 (enExample)
DE (1) DE69202594T2 (enExample)
DK (1) DK0501354T3 (enExample)
ES (1) ES2072644T3 (enExample)
TW (1) TW207498B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2123555A1 (en) * 1993-06-07 1994-12-08 Shinji Ohmori Intraocular irrigating solution
CA2213266A1 (en) * 1996-09-04 1998-03-04 Hideki Tsuruoka Method for isolation and purification of s-(1,2-dicarboxyethyl) glutathione
WO1999055329A1 (fr) * 1998-04-27 1999-11-04 Senju Pharmaceutical Co., Ltd. Medicament contre la cataracte
CN101704785B (zh) * 2009-11-16 2012-02-29 东南大学 有机二羧酸和其盐及其制备方法

Also Published As

Publication number Publication date
CA2061133A1 (en) 1992-08-28
EP0501354B1 (en) 1995-05-24
TW207498B (enExample) 1993-06-11
DE69202594D1 (de) 1995-06-29
KR0168459B1 (ko) 1999-01-15
ES2072644T3 (es) 1995-07-16
ATE122892T1 (de) 1995-06-15
JPH05112463A (ja) 1993-05-07
KR920016092A (ko) 1992-09-24
DK0501354T3 (da) 1995-10-16
EP0501354A1 (en) 1992-09-02

Similar Documents

Publication Publication Date Title
DE69530389T2 (de) Dexanabinol-derivate und ihre verwendung als neuroprotektive pharmazeutische zusammensetzungen
DE60026826T2 (de) Alterungsschutztetrapeptid, dieses enthaltende pharmazeutische zusammensetzungen und seine verwendung
DE69311130T2 (de) Arylpropionsäurederivat, verfahren zu seiner herstellung und seine verwendung als analgetikum
DE68914292T2 (de) Zusammensetzung zur Behandlung von ischämischen Störungen in Organen.
DE69400382T2 (de) Zusammensetzung zur Förderung des Lipidmetabolismus
EP0530446B1 (de) Verwendung von Schwefel enthaltenden Carbonsäuren zur Bekämpfung von pathophysiologisch bedingten Erregungsstörungen
DE3529529A1 (de) Verfahren zur herstellung einer stabilen modifikation von torasemid
DE69625877T2 (de) Verwendung von 5-HT1A Rezeptor-Liganden zur Behandlung des Glaukoms
DE69805334T2 (de) Derivate des vitamin e
DE69001722T2 (de) Entzuendungshemmende und/oder antiallergische zusammensetzung, die glutathionderivate enthaelt.
DE3744947C2 (enExample)
DE68915341T2 (de) Expektoranz, das ein Hydroxy-alkyl-cystein-Derivat enthält.
DE69001111T2 (de) Antikrebs-zusammensetzung.
DE69501359T2 (de) Verwendung von Phosphatdiestern zur Behandlung von Erkrankungen der Retina
DE3907688C2 (de) Salze von ungesättigten Fettsäuren mit Aminosäuren, Verfahren zu ihrer Herstellung sowie die Verwendung der ersteren und von weiteren derartigen Salzen
DE1767163C3 (de) Blutdrucksenkendes Arzneimittel
EP0166183B1 (de) Verwendung von Hydroxyindolderivaten zur Herstellung eines Arzneimittels zur Senkung des Blutdrucks
DE69202594T2 (de) Zusammensetzung gegen Katarakt.
WO1981001285A1 (fr) Ceto-acides carboxyliques substitues - procedes de leur preparation - leur utilisation et compositions medicamenteuses les contenant
DE69013431T2 (de) Anthocyanidine zur Behandlung von Augenkrankheiten.
DE69001004T2 (de) Zusammensetzung gegen leberkrankheiten.
DE3643119A1 (de) Therapeutische zusammensetzung fuer diabetes-komplikationen
DE69115528T2 (de) Neue pharmazeutische Verwendungen von Forskolin-Derivaten
DE3202561A1 (de) Lysinsalze der ((1-benzyl-1h-indazol-3-yl)-oxy)-essigsaeure, verfahren zu deren herstellung und diese enthaltende arzneimittel
DE69300945T2 (de) Fettstoffwechsel verbessernde Zusammensetzung.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee